Literature DB >> 18048641

Intracellular mechanisms regulating corticotropin-releasing hormone receptor-2beta endocytosis and interaction with extracellularly regulated kinase 1/2 and p38 mitogen-activated protein kinase signaling cascades.

Danijela Markovic1, Anu Punn, Hendrik Lehnert, Dimitris K Grammatopoulos.   

Abstract

Many important physiological roles of the urocortin (UCN) family of peptides as well as CRH involve the type 2 CRH receptor (CRH-R2) and downstream activation of multiple pathways. To characterize molecular determinants of CRH-R2 functional activity, we used HEK293 cells overexpressing recombinant CRH-R2beta and investigated mechanisms involved in attenuation of CRH-R2 signaling activity and uncoupling from intracellular effectors. CRH-R2beta-mediated adenylyl cyclase activation was sensitive to homologous desensitization induced by pretreatment with either UCN-II or the weaker agonist CRH. CRH-R2beta activation induced transient beta-arrestin1 and beta-arrestin2, as well as clathrin, recruitment to the plasma membrane. Beta-arrestin2 appeared to be the main beta-arrestin subtype associated with the receptor. This was followed by CRH-R2beta endocytosis in a mechanism that exhibited distinct agonist-dependent temporal characteristics. CRH-R2beta also induced transient activation of the ERK1/2 and p38MAPK signaling cascades that peaked at 5 min and returned to basal within 20-30 min. Unlike p38MAPK, activated ERK1/2 was localized both in the cytoplasm and nucleus. Experiments employing inhibitors of receptor endocytosis showed that CRH-R2beta-MAPK interaction does not require beta-arrestin, clathrin, or receptor endocytosis. Site-directed mutagenesis studies on CRH-R2beta C terminus showed that the amino acid cassette TAAV at the end of the C terminus is important for CRH-R2beta signaling because loss of a potential phospho-acceptor site in mutant receptors containing deletion or Ala substitution of the cassette TAAV resulted in reduced ERK1/2 activation and accelerated receptor internalization. These findings provide new insights about the signaling mechanisms regulating CRH-R2beta functional activity and determining its biological responses.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18048641      PMCID: PMC5419620          DOI: 10.1210/me.2007-0136

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  32 in total

1.  Differential regulation of corticotropin releasing factor 1alpha receptor endocytosis and trafficking by beta-arrestins and Rab GTPases.

Authors:  Kevin D Holmes; Andy V Babwah; Lianne B Dale; Michael O Poulter; Stephen S G Ferguson
Journal:  J Neurochem       Date:  2006-01-12       Impact factor: 5.372

2.  Modulation of the arrestin-clathrin interaction in cells. Characterization of beta-arrestin dominant-negative mutants.

Authors:  J G Krupnick; F Santini; A W Gagnon; J H Keen; J L Benovic
Journal:  J Biol Chem       Date:  1997-12-19       Impact factor: 5.157

3.  Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor.

Authors:  K Lewis; C Li; M H Perrin; A Blount; K Kunitake; C Donaldson; J Vaughan; T M Reyes; J Gulyas; W Fischer; L Bilezikjian; J Rivier; P E Sawchenko; W W Vale
Journal:  Proc Natl Acad Sci U S A       Date:  2001-06-19       Impact factor: 11.205

4.  Association of beta-arrestin with G protein-coupled receptors during clathrin-mediated endocytosis dictates the profile of receptor resensitization.

Authors:  R H Oakley; S A Laporte; J A Holt; L S Barak; M G Caron
Journal:  J Biol Chem       Date:  1999-11-05       Impact factor: 5.157

5.  Peptide ligand binding properties of the corticotropin-releasing factor (CRF) type 2 receptor: pharmacology of endogenously expressed receptors, G-protein-coupling sensitivity and determinants of CRF2 receptor selectivity.

Authors:  Sam R J Hoare; Susan K Sullivan; Jun Fan; Khamkeo Khongsaly; Dimitri E Grigoriadis
Journal:  Peptides       Date:  2005-03       Impact factor: 3.750

6.  Distinct conformations of the corticotropin releasing factor type 1 receptor adopted following agonist and antagonist binding are differentially regulated.

Authors:  Stephen J Perry; Sachiko Junger; Trudy A Kohout; Sam R J Hoare; R Scott Struthers; Dimitri E Grigoriadis; Richard A Maki
Journal:  J Biol Chem       Date:  2005-01-14       Impact factor: 5.157

7.  Corticotropin-releasing factor receptor 2 is a tonic suppressor of vascularization.

Authors:  Tracy L Bale; Frank J Giordano; Reed P Hickey; Yan Huang; Anjali K Nath; Kirk L Peterson; Wylie W Vale; Kuo-Fen Lee
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-28       Impact factor: 11.205

8.  A practical computer-based approach to the analysis of radioligand binding experiments.

Authors:  G A McPherson
Journal:  Comput Programs Biomed       Date:  1983 Aug-Oct

Review 9.  The molecular mechanisms underlying the regulation of the biological activity of corticotropin-releasing hormone receptors: implications for physiology and pathophysiology.

Authors:  Edward W Hillhouse; Dimitris K Grammatopoulos
Journal:  Endocr Rev       Date:  2006-02-16       Impact factor: 19.871

10.  Distinct beta-arrestin- and G protein-dependent pathways for parathyroid hormone receptor-stimulated ERK1/2 activation.

Authors:  Diane Gesty-Palmer; Minyong Chen; Eric Reiter; Seungkirl Ahn; Christopher D Nelson; Shuntai Wang; Allen E Eckhardt; Conrad L Cowan; Robert F Spurney; Louis M Luttrell; Robert J Lefkowitz
Journal:  J Biol Chem       Date:  2006-02-21       Impact factor: 5.157

View more
  25 in total

1.  Endoplasmic reticulum stress decreases intracellular thyroid hormone activation via an eIF2a-mediated decrease in type 2 deiodinase synthesis.

Authors:  Rafael Arrojo E Drigo; Tatiana L Fonseca; Melany Castillo; Matthias Salathe; Gordana Simovic; Petra Mohácsik; Balazs Gereben; Antonio C Bianco
Journal:  Mol Endocrinol       Date:  2011-11-03

Review 2.  Evidence for the role of corticotropin-releasing factor in major depressive disorder.

Authors:  R Parrish Waters; Marion Rivalan; D A Bangasser; J M Deussing; M Ising; S K Wood; F Holsboer; Cliff H Summers
Journal:  Neurosci Biobehav Rev       Date:  2015-08-10       Impact factor: 8.989

3.  Desensitization of human CRF2(a) receptor signaling governed by agonist potency and βarrestin2 recruitment.

Authors:  Richard L Hauger; J Alberto Olivares-Reyes; Sandra Braun; Judith Hernandez-Aranda; Christine C Hudson; Eric Gutknecht; Frank M Dautzenberg; Robert H Oakley
Journal:  Regul Pept       Date:  2013-06-29

Review 4.  Alternative splicing of G protein-coupled receptors: physiology and pathophysiology.

Authors:  Danijela Markovic; R A John Challiss
Journal:  Cell Mol Life Sci       Date:  2009-07-23       Impact factor: 9.261

Review 5.  Insights into mechanisms of corticotropin-releasing hormone receptor signal transduction.

Authors:  Dimitris K Grammatopoulos
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

6.  Sex- and corticotropin-releasing factor receptor 2- dependent actions of urocortin 1 during inflammation.

Authors:  Burcu Hasdemir; Pallavi Mhaske; Sreenivasan Paruthiyil; Elizabeth A Garnett; Melvin B Heyman; Mehrdad Matloubian; Aditi Bhargava
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2016-04-06       Impact factor: 3.619

7.  Quantification of beta-catenin signaling components in colon cancer cell lines, tissue sections, and microdissected tumor cells using reaction monitoring mass spectrometry.

Authors:  Yi Chen; Mike Gruidl; Elizabeth Remily-Wood; Richard Z Liu; Steven Eschrich; Mark Lloyd; Aejaz Nasir; Marilyn M Bui; Emina Huang; David Shibata; Timothy Yeatman; John M Koomen
Journal:  J Proteome Res       Date:  2010-08-06       Impact factor: 4.466

8.  Residue 17 of sauvagine cross-links to the first transmembrane domain of corticotropin-releasing factor receptor 1 (CRFR1).

Authors:  Iman Assil-Kishawi; Tareq A Samra; Dale F Mierke; Abdul B Abou-Samra
Journal:  J Biol Chem       Date:  2008-10-27       Impact factor: 5.157

Review 9.  Role of CRF receptor signaling in stress vulnerability, anxiety, and depression.

Authors:  Richard L Hauger; Victoria Risbrough; Robert H Oakley; J Alberto Olivares-Reyes; Frank M Dautzenberg
Journal:  Ann N Y Acad Sci       Date:  2009-10       Impact factor: 5.691

10.  Urocortin induced expression of COX-2 and ICAM-1 via corticotrophin-releasing factor type 2 receptor in rat aortic endothelial cells.

Authors:  Rongjian Zhang; Youhua Xu; Hong Fu; Juejin Wang; Lai Jin; Shengnan Li
Journal:  Br J Pharmacol       Date:  2009-08-19       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.